Status:
COMPLETED
Effect of Recombinant Human Interferon α-2b Spray on Herpangina
Lead Sponsor:
Children's Hospital of Fudan University
Collaborating Sponsors:
Tianjin Sinobioway Biomedicine Co.Ltd.
Hunan Children's Hospital
Conditions:
Herpangina
Eligibility:
All Genders
1-7 years
Phase:
PHASE4
Brief Summary
This is a multicenter, open，randomized controlled trial aiming to evaluate the effectiveness of recombinant human interferon α-2b spray compared with ribavirin treatment on pediatric patients with her...
Eligibility Criteria
Inclusion
- Subjects should meet all of the following:
- meet the diagnostic criteria for pediatric herpangina;
- ages 1-7 years, no limitation for gender;
- within 72 hours of onset;
- the main organs (heart, liver, kidney and lung) function normally;
- follow up according to requirements and be hospitalized for observation;
- the guardian is fully informed and signed informed consent.
Exclusion
- Subjects should be excluded if meet any of the following:
- have allergy history of interferon;
- heart failure, respiratory insufficiency,liver and kidney dysfunction or severe malnutrition and other serious disease, or immunodeficient;
- children with epilepsy or other neurological disorders;
- other pathogens exist at the same time;
- the researchers believe that it is not appropriate to participate in this study.
Key Trial Info
Start Date :
June 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2018
Estimated Enrollment :
668 Patients enrolled
Trial Details
Trial ID
NCT03266601
Start Date
June 1 2016
End Date
December 31 2018
Last Update
March 7 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital of Fudan University
Shanghai, China, 201102